Thromboembolic risk stratification in atrial fibrillation-beyond clinical risk scores

Area of Science:

• Cardiology
• Internal Medicine
• Public Health

Background:

• Atrial fibrillation (AF) is the most prevalent adult arrhythmia, with its global prevalence increasing due to aging populations.
• AF significantly elevates the risk of stroke and thromboembolic events, contributing to substantial morbidity and mortality.
• Current clinical risk scores for thromboembolism have limitations in accurately stratifying risk across diverse AF patient subgroups.

Purpose of the Study:

• To review and discuss advanced strategies for enhancing thromboembolic risk stratification in atrial fibrillation patients.
• To identify challenges and opportunities presented by new technologies and approaches in AF management.
• To provide insights into improving patient outcomes by optimizing prophylaxis decisions.

Main Methods:

• Literature review of current and emerging risk stratification tools for atrial fibrillation.
• Analysis of the utility of biomarkers and advanced imaging modalities in predicting thromboembolic events.
• Discussion of the implications of subclinical AF detection and the role of wearable devices.

Main Results:

• Traditional risk scores show modest discriminatory power, indicating a need for improved methods.
• Biomarkers and imaging offer potential for more precise risk assessment.
• Subclinical AF and data from wearable devices present new challenges and opportunities for risk stratification.

Conclusions:

• Enhanced thromboembolic risk stratification is crucial for optimizing prophylaxis in the growing AF population.
• Integrating novel biomarkers, imaging, and wearable device data may improve patient selection for anticoagulation.
• Addressing the challenges of subclinical AF and evolving technology is essential for future cardiology practice.